Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps
Executive Summary
Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January
You may also be interested in...
Sanofi Buys Out Arixtra Joint Venture With Organon; Expanded Label Coming
Sanofi-Synthelabo is taking over sole rights to Arixtra from Organon ahead of an expected label expansion for the antithrombotic agent
Sanofi Buys Out Arixtra Joint Venture With Organon; Expanded Label Coming
Sanofi-Synthelabo is taking over sole rights to Arixtra from Organon ahead of an expected label expansion for the antithrombotic agent
Sanofi/Organon Arixtra
Arixtra added to 425 hospital formularies in the U.S. and Europe as of July, Sanofi says. Sanofi/Organon launched Arixtra (fondaparinux) for deep vein thrombosis in the first quarter (1"The Pink Sheet" Dec. 17, 2001, p. 3). While Arixtra sales had a slow start in the first half, "formulary wins are in line with expectations," Sanofi said. The company expects Arixtra to gain full access to the low molecular weight heparin market in 2006; Sanofi estimates its approved use in hospital-based orthopedic surgery provides 14% access...